Breast Cancer Therapeutics Market Size, Trends And Forecast To 2032
The global Breast Cancer Therapeutics market size was valued at USD 28 billion in 2022 and is predicted to be worth USD 61.01 billion by 2032, with a CAGR of 8.1% from 2023 to 2032.
Key Pointers:
The growing incidence of breast cancer is amongst the major factors stimulating the overall market growth. According to the International Agency for Research on Cancer (WHO), in 2021, the incidence of breast cancer was 2,261,519, accounting for approximately 12.9% of the total cancer cases globally.
Further, the disease accounted for 684,999 mortalities in 2021. Thus, the high incidence and mortality rate associated with breast cancer is expected to render significant impact, driving the market expansion.
Breast cancer therapeutics can be defined as the treatment or management of breast cancer using therapeutic approach & drugs such as the targeted therapy, chemotherapy, hormonal therapy, and other therapeutics. These therapeutics abduct the growth and multiplication of cancerous cells by disrupting certain proteins or DNA.
However, several side effects associated with the use of breast cancer therapeutics along with the high cost of drugs may negatively impact the breast cancer therapeutics industry growth. Owing to adverse effects of chemotherapy, concerns have been raised regarding the heightened risk of chronic & acute effects among breast cancer patients. These patients receiving chemotherapy frequently experience side effects such as cardiac toxicity, pneumonitis (RP), arm lymph edema, retherapyive ysfunction, neuropathy, and skin changes among other complications.
Further, the adjuvant treatment may lead to bowel disturbance, neutropenia, radiation dermatitis, fatigue, and other complications. The host of negative effects associated with the breast cancer therapeutics may limit the therapy adoption and hamper the market demand.
The COVID-19 pandemic emerged as an unprecedented health concern and has slowed down the breast cancer therapeutics market growth. The coronavirus outbreak has disrupted the global economy, inflicting economic burden and financial adversities. Many sectors have witnessed drastic transition including the healthcare sector. Hospital admissions regarding COVID-19 affected patients were prioritized, with other medical procedures postponed.
According to the National Centers for Biotechnology Information (NCBI) article, in 2021, the COVID-19 pandemic caused delays in the screening and treatment of breast cancer patients owing to fear of infection and lockdown. The study reported a 15% drop in breast cancer patients admitted during the coronavirus outbreak. Similarly, as per the BMC Journal of Hematology and Oncology, the initial phase of pandemic hampered the Dutch national screening program and inflicted substantial burden on health care services that lead to delay in diagnosis and treatment of breast cancer patients. Pertaining to these developments, the breast cancer therapeutics market is projected to witness a slightly slow growth.
However, the rising incidence of breast cancer and increased mortality rate among breast cancer patients with acquired COVID-19 infection are expected to uplift the market size. Further, the reducing COVID-19 cases and initiatives taken by the authorities to facilitate the treatment of breast cancer patients would further benefit the market statistics. As a result, the market witnessed slow growth owing to delayed breast cancer diagnosis and treatment, although the industry is expected to follow the growth trajectory in the coming years.
Breast Cancer Therapeutics Market Segmentation And Key Players
| By Therapy | Regions Covered | Companies Profiled |
|
Targeted therapy Hormonal therapy Chemotherapy Immunotherapy |
North America Europe Asia-Pacific Latin America Middle East & Africa (MEA)
|
AstraZeneca Eli Lilly, & Co. Pfizer BMS Novartis Amgen Roche Merck |
Chapter 1. Introduction
1.1 Market definition
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Breast cancer therapeutics industry 3600 synopsis, 2023 - 2032
2.1.1 Business trends
2.1.2 Therapy trends
2.1.3 Regional trends
Chapter 3 Breast Cancer Therapeutics Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2023 – 2032
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Growing burden of breast cancer
3.3.1.2 Advancements in cancer biology and pharmacology promoting drug development
3.3.1.3 Increasing investments in R&D
3.3.1.4 Launch of several diagnostic and screening programs
3.3.1.5 Favourable insurance and reimbursement policies
3.3.2 Industry pitfalls & challenges
3.3.2.1 Side-effects associated with breast cancer drugs
3.3.2.2 High cost of drugs
3.4 Growth potential analysis
3.4.1 By therapy
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Reimbursement scenario
3.8 Pipeline analysis
3.9 Porter’s analysis
3.10 Competitive landscape, 2021
3.10.1 Company matrix analysis, 2021
3.11 PESTEL analysis
Chapter 4 Breast Cancer Therapeutics Market, By Therapy
4.1 Key segment trends
4.2 Targeted therapy
4.2.1 Market size, by region, 2023 - 2032
4.3 Hormonal therapy
4.3.1 Market size, by region, 2023 - 2032
4.4 Chemotherapy
4.4.1 Market size, by region, 2023 - 2032
4.5 Immunotherapy
4.5.1 Market size, by region, 2023 - 2032
Chapter 5 Breast Cancer Therapeutics Market, By Region
5.1 Key regional trends
5.2 North America
5.2.1 Market size, by country, 2023 - 2032
5.2.2 Market size, by therapy, 2023 - 2032
5.2.3 U.S.
5.2.3.1 Market size, by therapy, 2023 - 2032
5.2.4 Canada
5.2.4.1 Market size, by therapy, 2023 - 2032
5.3 Europe
5.3.1 Market size, by country, 2023 - 2032
5.3.2 Market size, by therapy, 2023 - 2032
5.3.3 Germany
5.3.3.1 Market size, by therapy, 2023 - 2032
5.3.4 UK
5.3.4.1 Market size, by therapy, 2023 - 2032
5.3.5 France
5.3.5.1 Market size, by therapy, 2023 - 2032
5.3.6 Italy
5.3.6.1 Market size, by therapy, 2023 - 2032
5.3.7 Spain
5.3.7.1 Market size, by therapy, 2023 - 2032
5.4 Asia Pacific
5.4.1 Market size, by country, 2023 - 2032
5.4.2 Market size, by therapy, 2023 - 2032
5.4.3 China
5.4.3.1 Market size, by therapy, 2023 - 2032
5.4.4 India
5.4.4.1 Market size, by therapy, 2023 - 2032
5.4.5 Japan
5.4.5.1 Market size, by therapy, 2023 - 2032
5.4.6 Australia
5.4.6.1 Market size, by therapy, 2023 - 2032
5.4.7 South Korea
5.4.7.1 Market size, by therapy, 2023 - 2032
5.5 Latin America
5.5.1 Market size, by country, 2023 - 2032
5.5.2 Market size, by therapy, 2023 - 2032
5.5.3 Brazil
5.5.3.1 Market size, by therapy, 2023 - 2032
5.5.4 Mexico
5.5.4.1 Market size, by therapy, 2023 - 2032
5.5.5 Argentina
5.5.5.1 Market size, by therapy, 2023 - 2032
5.6 Middle East and Africa
5.6.1 Market size, by country, 2023 - 2032
5.6.2 Market size, by therapy, 2023 - 2032
5.6.3 South Africa
5.6.3.1 Market size, by therapy, 2023 - 2032
5.6.4 Saudi Arabia
5.6.4.1 Market size, by therapy, 2023 - 2032
5.6.5 UAE
5.6.5.1 Market size, by therapy, 2023 - 2032
Chapter 6 Company Profiles
6.1 Competitive dashboard, 2021
6.2 AstraZeneca plc
6.2.1 Business overview
6.2.2 Financial data
6.2.3 Therapy landscape
6.2.4 Strategic outlook
6.2.5 SWOT analysis
6.3 Eli Lilly & Co, Inc.
6.3.1 Business overview
6.3.2 Financial data
6.3.3 Therapy landscape
6.3.4 Strategic outlook
6.3.5 SWOT analysis
6.4 Pfizer, Inc.
6.4.1 Business overview
6.4.2 Financial data
6.4.3 Therapy landscape
6.4.4 Strategic outlook
6.4.5 SWOT analysis
6.5 Bristol Myers Squibb
6.5.1 Business overview
6.5.2 Financial data
6.5.3 Therapy landscape
6.5.4 Strategic outlook
6.5.5 SWOT analysis
6.6 Novartis AG
6.6.1 Business overview
6.6.2 Financial data
6.6.3 Therapy landscape
6.6.4 Strategic outlook
6.6.5 SWOT analysis
6.7 Amgen
6.7.1 Business overview
6.7.2 Financial data
6.7.3 Therapy landscape
6.7.4 Strategic outlook
6.7.5 SWOT analysis
6.8 F. Hoffmann La Roche AG
6.8.1 Business overview
6.8.2 Financial data
6.8.3 Therapy landscape
6.8.4 Strategic outlook
6.8.5 SWOT analysis
6.9 Merck & Co, Inc.
6.9.1 Business overview
6.9.2 Financial data
6.9.3 Therapy landscape
6.9.4 Strategic outlook
6.9.5 SWOT analysis
6.10 Sanofi
6.10.1 Business overview
6.10.2 Financial data
6.10.3 Therapy landscape
6.10.4 Strategic outlook
6.10.5 SWOT analysis
6.11 Eisai Co., Ltd.
6.11.1 Business overview
6.11.2 Financial data
6.11.3 Therapy landscape
6.11.4 Strategic outlook
6.11.5 SWOT analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers